Pharmacologic, Pharmacokinetic, and Pharmacogenomic Aspects of Functional Gastrointestinal Disorders

Michael Camilleri, 1 Lionel Buéno, 2,† Viola Andresen, 3 Fabrizio De Ponti, 4 Myung-Gyu Choi, 5 and Anthony Lembo 6

1 Mayo Clinic College of Medicine, Mayo Clinic, Rochester, Minnesota; 2 INRA, Toulouse, France; 3 Israelitic Hospital, University of Hamburg, Hamburg, Germany; 4 Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy; 5 Department of Gastroenterology, The Catholic University of Korea College of Medicine Internal Medicine, Seoul, Korea; and 6 GI Motility Laboratory, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, Massachusetts

This article reviews medications commonly used for the treatment of patients with functional gastrointestinal disorders (FGIDs). Specifically, we review the animal models that have been validated for the study of drug effects on sensation and motility; the preclinical pharmacology, pharmacokinetics, and toxicology usually required for introduction of new drugs; the biomarkers that are validated for studies of sensation and motility end points with experimental medications in humans; the pharmacogenomics applied to these medications and their relevance to the FGIDs; and the pharmacology of agents that are applied or have potential for the treatment of FGIDs, including psychopharmacologic drugs.

Keywords: Pain; Diarrhea; Constipation; Animal Models; Dyspepsia; Transit; Sensation.

Medications are commonly used for the treatment of patients with functional gastrointestinal disorders (FGIDs). This article summarizes the pharmacokinetics and pharmacology of medications used to treat FGIDs. Methods included literature review, consensus evaluation of the evidence for each topic assigned originally to 1 or 2 authors, and broader review at a harmonization session as part of the Rome IV process. Clinicians and basic scientists involved in the treatment or investigation of FGIDs or disease models need to have a comprehensive understanding of a vast range of medications.

Preclinical Pharmacology: Animal Models Validated for Study of Sensation and Motility

The development of new drugs for the treatment of patients with FGIDs is facilitated by preclinical animal models that must reproduce the pathophysiology of FGIDs as closely as possible. This section reviews the most commonly used animal models of visceral pain and disturbed gastrointestinal motility (Figure 1).

Visceral Pain

Mechanical Stimuli. Experiments are performed in awake or anesthetized rats, and the most frequently used stimulus of pain in animals is distention of a gut segment with a balloon connected to a barostat to measure simultaneously compliance and the response to gastrointestinal distention. Balloons can be acutely or chronically implanted in the gut. 1 A number of factors influence reproducibility of balloon distention studies across laboratories: balloon construction and unfolding, distention protocols, and frequency of balloon distentions in the same animal (which can lead to sensitization), and species (eg, rats vs mice) or strain differences within species.

Chemical Stimuli. In rats, infusion of glycerol into the colon through an implanted catheter induces abdominal cramps that are typically demonstrated by observed behaviors (eg, back arching or writhing) or by psychoactive responses, including reflex electromyographic activity measured in the abdominal wall muscles (discussed in the section End Points Used to Evaluate Sensation). 6 Intracolic injection of glycerol results in an increase in long spike burst activity, which was eliminated by previous administration of lidocaine, suggesting there is an induction of a viscerovisceral reflex. 7 Two separate studies provide contradictory results regarding the role of glycerol-induced activation of serotonin/5-hydroxytryptamine (5-HT) type 3 receptors on visceral afferent pathways. The 5-HT3 antagonist granisetron did not modify this reflex in a human study, whereas alosetron significantly attenuated the glycerol-induced visceral pain in rats. 2,3,8 It is conceivable that glycerol’s effects on contractile activity and tone might be inhibited by alosetron independently of any effects on visceral afferents or vissus compliance. 8 Other stimuli are used to sensitize the colon to balloon distention in order to investigate visceral pain modulation in animal models; they produce an initial inflammatory response 5 that resolves, but

Abbreviations used in this paper: CFTR, cystic fibrosis transmembrane regulator; cGMP, cyclic guanosine monophosphate; CYP, cytochrome P450; FD, functional dyspepsia; FDA, Food and Drug Administration; FGID, functional gastrointestinal disorder; GC-C, guanylate cyclase-C; GI, gastrointestinal; 5-HT, 5-hydroxytryptamine; IBS, irritable bowel syndrome; IBS-C, constipation-predominant irritable bowel syndrome; IBS-D, diarrhea-predominant irritable bowel syndrome; OIC, opioid-induced constipation.

†Deceased.
Animal models for preclinical pharmacology

Threshold  | Behavioral  | Tone  | Compliance
---|---|---|---
Sensitivity  |  |  |  
Afferent firing  | Pseudo-affective  | MMC  | Transit

Figure 1. End points in experimental animal models of sensitivity and motility are applied in preclinical pharmacology of lead compounds.

later leads to sensitization of visceral afferents. Other chemical irritants include trinitrobenzene sulfonic acid, dioctyl sodium sulfosuccinate, and zymogen and parasite infestations (such as *Nippostrongylus brasiliensis* or *Trichinella spiralis*). Long-term colonic hyperalgesia may also be induced by colonic inflammation. At present, there is no consensus on the best model to study visceral pain.

Nonchemical Models Used to Study Visceral Sensitivity

Other models used to study colonic and rectal hypersensitivity are stress (eg, maternal deprivation, water avoidance models) and lipopolysaccharide injection. Long-term colonic hyperalgesia may be induced by neonatal maternal deprivation.

End Points Used to Evaluate Sensation

Nociceptive responses to stimuli, called "pseudo-affective" responses, are brainstem or spinal reflexes that cease when the noxious stimulus is terminated. The most commonly used end point in the rat is the contraction of abdominal muscles induced by rectal or colorectal distention; the contractions are typically recorded by electromyography. The numbers of spike bursts or integrated signals correspond to abdominal contractions during the period of distension, and they correlate with the intensity of the stimulus applied.

In mice, colorectal distention triggers only one sustained contraction at the onset of the distention. It is, however, also possible that the electromyographic recording may reflect contractions associated with a distention-induced defecation reflex, rather than being a measure of pain. This inference is supported by the observation that gastric distention in rats does not induce abdominal contractions. In contrast, stretching of the body or lifting of the head and electromyography of neck muscles appear to reflect nociceptive responses to gastric distention.

Visceral distension also induces viscerovisceral reflexes, such as relaxation of anal sphincters during rectal distention or rectocolonic inhibition of gastric emptying. Change in blood pressure is a pseudo-affective response widely used to assess visceral pain. Cardiovascular and muscular responses are mediated via brainstem reflexes; both are vigorous in decerebrated, but not spinalized, rats.

Electrophysiologic recordings from sensory neurons or second order neurons in the spinal cord may provide the most direct evidence that a drug alters afferent function.

Measurements of the effect of the medication on viscus compliance are essential to differentiate effects on volume thresholds to activate sensory fibers from drug-induced contraction or relaxation.

Several behavioral end points have been used and involve brain centers higher than the brainstem. They do not cease when the noxious stimulus is terminated and, therefore, are not pseudo-affective responses. Referred somatic hyperalgesia is evaluated in mice by application of von Frey hairs on the abdomen; the subsequent behavioral response is a measure of sensation. Functional magnetic resonance imaging studies of rat brain activity in response to colorectal distention have also been reported.

Allodynia and Hyperalgesia

Several models permit evaluation of alldynia (decrease in the sensitivity threshold to distention) and hyperalgesia (enhanced response to painful stimulus). Gastric hypersensitivity to distention has been induced by inflammation and intestinal hypersensitivity by helminth infection.

Motility

The techniques used to record motility or measure transit in animals may differ from techniques used in humans, but the end points are identical.
Delayed Gastric Emptying
Numerous stressors have been proposed to inhibit gastric emptying in rats, including restraint, acoustic stress, cold stress, combined acoustic and cold stress, and passive avoidance. Prolonged colonic distension inhibits gastric emptying, and this is considered relevant because, in humans, voluntary suppression of defecation for 4 days inhibits gastric emptying.26 Another experimental method used to inhibit gastric emptying is duodenal infusion of lipids in humans or animals (reviewed in Lee and Tack27). 

Altered Duodenojejunal Migrating Motor Complex Pattern
Acute stress affects migrating motor complex patterns,28 however, there are no models of chronic disruption of the migrating motor complex in animals.

Altered Colonic Motility and Transit
Intestinal motility can be measured in animal models of gastrointestinal (GI) transit. A traditional model is the charcoal meal model, where animals are administered test agents before or followed by a bolus of a charcoal meal. The distance traveled by this charcoal along the GI tract is measured and quantified as a percentage of distance traveled after administering vehicle alone.29 Colonic transit in response to fluid hypersecretion is harder to measure in rodents due to the high fluid reabsorption in the cecum; however, preclinical models to study distal colonic propulsion have been described in rodents.24 Colonic motility can be inhibited by drugs such as α2-adrenoceptor and μ-opioid receptor agonists. Stress has been used to stimulate colonic motility, colonic transit, and fecal excretion in rats.25 Induction of intestinal peristalsis by pharmacologic agents has also been modeled using isolated guinea pig colonic segments.26

In summary, because the present knowledge of the pathophysiology of FGIDs is limited, selection of one or more reliable animal models is not possible. It is also difficult, based on results in a single animal model, to predict efficacy of a compound in clinical trials. Studying more than one animal model can enhance the probability of selecting effective drugs for further development. Several medications with track records of proven efficacy in animal models (for both transit and sensation) were subsequently shown to have clinical efficacy (eg, 5-HT4 agonists, 5-HT3 antagonists, opioid agonists, guanylate cyclase-C receptor agonists); however, other classes of medications that appeared to influence sensory functions in animal models were not efficacious in clinical trials (eg, NK3 antagonist, β2-adrenergic agonist). In addition, it is worth emphasizing that pain is not the only symptom of FGIDs affecting quality of life, and animal models providing information on motility effects may be relevant to the assessment of new drugs.

Human Studies of Motility and Sensation: Utility in Drug Development for Functional Gastrointestinal Disorders
This section reviews the application of physiologic tests as potential biomarkers used to understand the mode of action and to predict efficacy of new drug treatments of FGIDs.

Measurements of Colonic Transit
The radiopaque marker test for colonic transit is a commonly performed and widely available test used to assess whole-gut transit time. Studies with fiber or loperamide suggest that overall effects of these therapies can be predicted by the marker transit test, although there was considerable overlap.27,28 Examples from the literature support the use of detailed scintigraphic colonic transit measurement in the development of medications for irritable bowel syndrome (IBS)—associated changes in bowel function. Alosetron, a 5-HT3 receptor antagonist that slows colonic transit, was shown to be effective in female diarrhea-predominant IBS (IBS-D) patients,29 and tegaserod and prucalopride, 5-HT4 receptor agonists that accelerate colonic transit, are effective in constipation-predominant IBS (IBS-C) and functional constipation.30–34 Linaclotide, a novel agonist of guanylate cyclase-C, accelerated ascending colonic transit and altered bowel function; thus, it was shown to be effective in IBS-C.35–37

Intraluminal Measurements of Rectal or Colonic Motility and Sensation
Intracolonic measurements of postprandial tone showed the potential of 5-HT3 receptor antagonists to prevent diarrhea and other postprandial symptoms in IBS and carcinoid diarrhea.38 However, measurements of rectal or colonic sensation in human subjects do not reliably predict clinical efficacy. Changes in rectal sensitivity are observed with octreotide and opiates, but rectal sensory thresholds are not altered by tegaserod when using rapid distention.39–44

Gastric Biomarkers in Functional Dyspepsia
Gastric emptying rates, gastric electrical rhythm, gastric sensitivity, and gastric accommodation are targets for testing new drugs. Gastric emptying rates can explain symptoms and aid in diagnosis of gastroparesis. Scintigraphic gastric emptying has been a classic measurement for testing drug efficacy in gastroparesis; however, the prediction of clinical efficacy is not consistent.45,46 A recent extensive review questions the use of gastric emptying measurement to direct drug development for gastroparesis.47 This analysis is also complicated by the occurrence of tachyphylaxis to some medications and by changes in gastric emptying rate with placebo.48–51

Gastric accommodation is a new target for treatment, as it reflects meal-related satiety. The gastric barostat is the gold standard test used to measure compliance, tone, and
sensitivity. The κ-opioid agonist fedotozine and the 5-HT1A receptor agonist R-137696 produced acute effects on barostat measurements of sensitivity or tone that did not translate into significant clinical benefit during placebo-controlled studies of several weeks in functional dyspepsia (FD).52,53 Single-photon emission computed tomography and magnetic resonance imaging can evaluate accommodation by measuring gastric volume, but their usefulness has not been proven in clinical trials.

Induction of symptoms by a standardized provocative meal of water or a liquid nutrient drink or a solid meal shows differences between healthy controls and FD, and was used in clinical trials.54-56 One open trial of the dopamine-2 receptor antagonist and acetylcholinesterase inhibitor itopride (discussed further in the subsection Dopamine Receptor Antagonists) demonstrated that a provocative meal can quantify dyspeptic symptoms and reflected therapeutic effects of itopride treatment in FD. However, it is still unclear whether changes in symptom severity after meal provocative tests will prove effective predictors of the clinical efficacy of medications.

Combined use of the nutrient drink test with assessment of symptoms, and measurement of gastric volume and emptying or intragastric pressure monitoring, may simultaneously measure several potential biomarkers.57-59 Improved methods or further validation of those mentioned will more accurately assess changes in symptoms and sensorimotor function in future trials.

Preclinical Considerations

An outline of some general pharmacodynamic, pharmacokinetic, and safety aspects that are important for the development of new drugs for FGIDs is included in the Supplementary Material.

Pharmacokinetics

Ideal pharmacokinetics features of a drug with systemic action are the ability to reach clinically relevant drug concentrations at the target receptor; half-life or dosage formulation suitable for once daily administration; not a cytochrome P450 (CYP) substrate (lack of drug interactions); no metabolites with different or unwanted pharmacologic actions; and no interactions with food.

CYP2D6, CYP3A4, and CYP2C19 are important isoenzymes because of their involvement in the metabolism of many drugs and drug–drug interactions. The prevalence of altered CYP450 differs among different populations. Figure 2 shows the distribution of CYP2 altered activity variants in different geographic regions.60

Significant interactions with these enzymes should be ruled out in early drug discovery and may be achieved by computational prediction. Specifically, it is important to distinguish between pharmacokinetic modification resulting from drug metabolism by one of the enzymes vs drug interactions, which may be inhibition or induction, at one of the enzymes. In both situations, drug–drug interactions can occur, if inhibition or induction occurs at clinically relevant doses.

Principles of Pharmacogenomics in Functional Gastrointestinal Disorders

Pharmacogenetics refers to the study of individual variations in DNA sequence related to drug response. Pharmacogenomics is the study of the variability of the expression of individual genes relevant to disease susceptibility as well as drug response at cellular, tissue, individual, or population levels.

Polymorphisms may be markers associated with predisposition to FGIDs. For example, there may be an inflammatory or genetic component (eg, serotonin transporter, polymorphism in 5-hydroxytryptamine transporter linked polymorphic region) in some cases of IBS,61,62 or polymorphism (C825T) in the gene controlling G-protein synthesis in functional dyspepsia and IBS.63 Such genetic variations can influence response to medications. There may also be genetic polymorphisms in drug metabolism. For instance, the number of functional CYP2D6 genes determines the pharmacokinetics and plasma levels of the commonly used tricyclic agent, nortriptyline,64 or the action of codeine (which is converted to morphine by the CYP2D6 isoenzyme to be effective). Note also that several antidepressants are metabolized by these enzymes, and this might affect their clinical efficacy and safety.

Genetic polymorphisms may also involve transporters65 that may influence drug response. Two examples of pharmacodynamic variation in FGIDs are provided. 5-Hydroxytryptamine transporter linked polymorphic region polymorphisms in the gene SLC6A4 (solute carrier family 6 [neurotransmitter transporter], member 4) were associated with a greater colonic transit response in those with long homozygous polymorphisms compared to those with heterozygous or short homozygous polymorphisms in IBS-D.66 Conversely, IBS-C patients carrying the S allele of 5-hydroxytryptamine transporter linked polymorphic region have greater response to the 5-HT4 agonist tegaserod.67

Holtmann et al68 found that GN B3 polymorphisms were predictors of symptom outcomes in FD, based on the rationale that G proteins act as second messengers and may influence multiple receptor-mediated mechanisms.

Thus, pharmacogenetics may affect drug response and need to be considered in drug development programs and in clinical therapeutics in FGIDs. Further examples and discussion of pharmacogenetics in IBS are provided in the Supplementary Materials.

The conclusion as far as pharmacodynamics is that clinicians and basic investigators involved in the treatment or investigation of FGIDs or disease models need to have a comprehensive understanding of a vast range of medications. It is anticipated that the interactions among basic scientists, applied pharmacologists, and clinical trials will lead to better treatment for these disorders.

Human Pharmacology: Nonpsychotropic Agents

Gastrointestinal motor and sensory functions can be altered through several pharmacologic approaches; the
most important are summarized in Supplementary Table 1 and are discussed in this section. However, it is also important to recognize 2 other classes of agents commonly used in FGIDs: laxatives in the treatment of constipation (alone or in IBS-C) and probiotics. Several meta-analyses of pharmacologic treatments for IBS have been published in recent years. Although not a focus of this article, the pharmacologic actions of psychotropic drugs on monoamine reuptake and receptors are summarized in Supplementary Table 2. Figure 3 shows potential cellular and mechanistic targets for drug action in functional and motility disorders. Figure 4 provides a summary of receptors located on different cellular targets and their potential as treatments for FGIDs. Figure 5 summarizes the interaction of gut mucosal barrier, microbiome, and gut–brain interactions in FGIDs, focusing on colonic disorders.

**Upper Gastrointestinal Tract:**

**Gastroparesis, Functional Dyspepsia**

**Current Drug Treatments for Gastroparesis or Functional Dyspepsia**

**Serotonergic agents.** Serotonin, or 5-HT, plays a key role in the control of gastrointestinal motility, sensitivity, and secretion. Actions of 5-HT are terminated by the action of the serotonin transporter, which is inhibited by selective serotonin reuptake inhibitor antidepressants. Selective serotonin reuptake inhibitor alter motility in the stomach, small bowel, and colon, but, to date, no convincing beneficial therapeutic effects have been reported in FGIDs. Several 5-HT receptor types are present on nerves and smooth muscle and mediate multiple effects on gut motility, secretion, and sensation.

5-HT<sub>4</sub> receptor agonists, such as prucalopride or mosapride, act on intrinsic neurons to stimulate esophageal, gastric, small bowel, and colonic transit in health, in gastroesophageal reflux disease, in FD, in constipation, and in IBS-C. In the stomach, 5-HT<sub>4</sub> receptor agonists enhance (postprandial) proximal gastric volumes in health, but do not alter sensation. While prucalopride has been studied mainly in the lower GI tract and is primarily approved for the treatment of constipation (outside the United States), mosapride has also been investigated in the upper GI tract and is approved for the treatment of dyspepsia and gastroesophageal reflux disease in a variety of Asian and South American countries. Supplementary Table 3 shows a comparison of novel 5-HT<sub>4</sub> agonists that are efficacious in stimulating gut motility or transit and are sufficiently selective to predict clinical safety from cardiovascular perspectives (discussed in section on constipation and IBS-C).

**Dopamine receptor antagonists.** Dopamine-2 receptor antagonists have gastroprokinetic effects and central
antiemetic properties resulting in suppression of nausea and vomiting. Although metoclopramide and domperidone are used clinically in the treatment of FGIDs and gastroparesis, efficacy has not been established by high-quality studies. and treatment is recommended for short periods. A recent 4-week trial of oral dissolving metoclopramide shows efficacy in gastroparesis compared with placebo. It should be kept in mind that domperidone is listed among drugs with known risk of torsades de pointes, and the European Medicines Agency Pharmacovigilance Committee recommended restrictions on its use (www.crediblemeds.org).

Itopride is a benzamide that acts as a dopamine-2 receptor antagonist and an acetylcholinesterase inhibitor. Itopride has been investigated in FD with conflicting results. It is approved for the treatment of FD in Asia.

Motilides. Activation of motilin receptors on smooth muscle and cholinergic nerves enhances gastric contractility. Motilin receptor agonists, such as erythromycin, azithromycin, and clarithromycin enhance antral contractility, fundic tone, and gastric emptying in health and in gastroparesis. However, the symptomatic impact of enhanced empting by erythromycin in gastroparesis has
been questioned. The occurrence of tachyphylaxis with erythromycin and some motilides (eg, ABT-229) may also be an important factor.

A novel motilin receptor agonist (that does not appear to be associated with tachyphylaxis) is the experimental drug, camicinal. It is efficacious in vitro and has been shown to induce phasic contractions and increase gastrointestinal motility in conscious dogs.

Acetylcholinesterase inhibitor. Acotiamide is an acetylcholinesterase inhibitor that was recently approved in Japan for the treatment of FD. In phase 2 trials conducted in Europe, United States, and Japan, acotiamide had beneficial effects in FD, particularly for meal-related FD symptoms, such as postprandial fullness, upper abdominal bloating, and/or early satiation. A 4-week, phase 3 trial conducted in Japan in patients with postprandial distress syndrome confirmed the efficacy of acotiamide, 100 mg 3 times a day, in meal-related symptoms (ie, postprandial fullness, upper abdominal bloating and early satiation) compared with placebo.

New Drugs for Treatment of Gastroparesis and Functional Dysplasia

Ghrelin agonists: RM-131. TZP-101 (ulimorelin, an intravenous formulation) and TZP-102 (oral) were not consistently efficacious in early trials.

Relamorelin, a pentapeptide synthetic ghrelin agonist, has a longer plasma half-life and >100 times greater potency than native ghrelin in reversing ileus in rats and primates. In a randomized, placebo-controlled single-dose study, relamorelin accelerated gastric emptying in type 2 diabetes mellitus patients with gastrointestinal cardinal symptoms and prior documentation of delayed gastric emptying. In a large (n = 204) 4-week, phase 2b study in patients with diabetic gastroparesis, relamorelin, 10 µg given subcutaneously twice daily, improved gastric emptying and reduced vomiting episodes. Larger studies with longer treatment duration for the assessment of symptom improvement in gastroparesis are warranted.

Motilin receptor agonists. Camicinal (GSK962040) is a small molecule, non-motilide motilin receptor agonist that selectively activates the motilin receptor in humans and has been evaluated to determine safety and tolerability in humans. It is currently being investigated in phase 2 trials (NCT01262898).

Relamorelin, a pentapeptide synthetic ghrelin agonist, has a longer plasma half-life and >100 times greater potency than native ghrelin in reversing ileus in rats and primates. In a randomized, placebo-controlled single-dose study, relamorelin accelerated gastric emptying in type 2 diabetes mellitus patients with gastrointestinal cardinal symptoms and prior documentation of delayed gastric emptying. In a large (n = 204) 4-week, phase 2b study in patients with diabetic gastroparesis, relamorelin, 10 µg given subcutaneously twice daily, improved gastric emptying and reduced vomiting episodes. Larger studies with longer treatment duration for the assessment of symptom improvement in gastroparesis are warranted.

Motilin receptor agonists. Camicinal (GSK962040) is a small molecule, non-motilide motilin receptor agonist that selectively activates the motilin receptor in humans and has been evaluated to determine safety and tolerability in humans. It is currently being investigated in phase 2 trials (NCT01262898).

Motilin agonists may increase gastric tone or inhibit gastric accommodation and, potentially, worsen symptoms, even when gastric emptying improves.

Cholecystokinin. Cholecystokinin has multiple effects on gastrointestinal motility and secretion. Clinical usefulness of cholecystokinin-1 receptor antagonists, such as loxiglumide and dexloxiglumide, is uncertain.
Capsaicin. The transient receptor potential ion channel of the vanilloid type 1 (transient receptor potential cation channel, vanilloid member 1), expressed by primary afferent neurons, is a chemo- and thermoreceptor that may be up-regulated in some FGIDs.\textsuperscript{116} Long-term administration of capsaicin, which is a transient receptor potential cation channel, vanilloid member 1 agonist, was more effective than placebo in decreasing symptoms in FD.\textsuperscript{117}

Cannabinoids. Cannabinoid CB1 receptors are expressed on nociceptive primary afferents and some enteric neurons. CB1 receptor agonists slow gastrointestinal transit in animals by inhibiting acetylcholine release. \textsuperscript{5}-9-Tetrahydrocannabinol has strong antiemetic properties and delays gastric emptying in humans.\textsuperscript{118,119} It is unclear whether the abuse potential of CB1 agonists would preclude regulatory approval for treatment of FGIDs.

Chronic Constipation and Irritable Bowel Syndrome With Constipation

Current drug treatments. A discussion of the large number of available laxatives for chronic constipation is beyond the scope of this article. Among treatments for IBS-C, there is one large randomized controlled trial of polyethylene glycol showing improvement of constipation, but not pain.\textsuperscript{120}

Novel drug developments. There are 3 drug categories under development for treating chronic idiopathic constipation and IBS-C: 5-HT\textsubscript{4} receptor agonists, intestinal secretagogues, and bile acid modulators. Medications are being developed for specific treatment of opioid-induced constipation (OIC). Enhancing coordinated motor function is conceptually attractive, based on the demonstration of increased but uncoordinated motility, or retrograde or nonpropagated colonic contractility in disorders associated with constipation.\textsuperscript{121,122}

5-Hydroxytryptamine type 4 receptor agonists. 5-HT is an important neurotransmitter and paracrine signaling molecule involved in gastrointestinal secretion, sensation, and motility.\textsuperscript{123} 5-HT\textsubscript{4} receptors are expressed by enteric neurons and in the heart. 5-HT\textsubscript{4} receptor agonists facilitate fast excitatory cholinergic synaptic transmission between enteric neurons, which stimulates gastrointestinal motility and secretion.\textsuperscript{34,77} Activation of colonic mucosal 5-HT\textsubscript{4} receptors can inhibit visceral hypersensitivity in rodents.\textsuperscript{124}

Prucalopride, a new 5-HT\textsubscript{4} receptor agonist, has >150-fold greater selectivity for the 5-HT\textsubscript{4} receptors than for the \textit{I}_K_s channel and other 5-HT receptors.\textsuperscript{125} Prucalopride, mosapride, and 3 other 5-HT\textsubscript{4} receptor agonists (velusetrag, naronapride, and YKP10811) in recent and current development, including human trials are summarized in Supplementary Table 3. With high intrinsic activity and great specificity at intestinal 5-HT\textsubscript{4} receptors and with low intrinsic activity in cardiac muscle, these drugs have greater cardiovascular safety in comparison with older 5-HT\textsubscript{4} agonists.\textsuperscript{125}

There is considerable evidence supporting prucalopride’s pharmacodynamic and clinical efficacy and safety in patients with chronic constipation.\textsuperscript{126-132} Prucalopride did not show significant adverse effects in a study of elderly patients.\textsuperscript{133} Doses of 2 mg per day in adults and 1 mg per day in the elderly were approved for chronic constipation by the European Medicines Agency and a number of other regulatory bodies outside the United States.

Velusetrag and naronapride are in development stages (see Supplementary Table 3).\textsuperscript{134-136} YKP10811 is a 5-HT\textsubscript{4} receptor agonist that enhances colonic transit and improves stool consistency, and it reduced pain in an animal model of IBS.\textsuperscript{137,138} Intestinal Cl\textsuperscript{−} secretagogues. Cl\textsuperscript{−} secretagogues enter enterocytes through the basolateral Na\textsuperscript{+}-K\textsuperscript{+}-2Cl\textsuperscript{−} co-transporter. Na\textsuperscript{+} and K\textsuperscript{+} are then exported through the Na\textsuperscript{+}/K\textsuperscript{+}, ATPase, and KCNQ1/KCNE3 heteromeric K\textsuperscript{+} channels. Cl\textsuperscript{−} secretion in the apical membrane of epithelial cells occurs through cystic fibrosis transmembrane regulator (CFTR) and ClC-2 Cl\textsuperscript{−} channels\textsuperscript{139} and is activated by intracellular Ca\textsuperscript{2+} and cyclic guanosine monophosphate (cGMP).

Lubiprostone and linaclotide are approved drugs, while plecanatide and tenapanor are still in drug development (Supplementary Table 4).\textsuperscript{140} Lubiprostone is a bicyclic fatty acid, most closely related in structure to 15-keto-13,14-dihydro-PGE\textsubscript{1}, without the functional characteristics of PGE\textsubscript{1}.\textsuperscript{141,142} It stimulates intestinal Cl\textsuperscript{−} secretion through apical membrane ClC-2 channels and CFTR; the action on CFTR is still controversial, with recent data suggesting CFTR is not a target of lubiprostone at relevant concentrations.\textsuperscript{144} Lubiprostone has demonstrated efficacy in chronic constipation (24 µg bid) and in IBS-C (8 µg bid), and is approved by the US Food and Drug Administration (FDA) and several other countries.\textsuperscript{143,145-150} Lubiprostone is also approved for treatment of OIC (discussed in the section Other Medications for OIC).

Linaclotide and plecanatide activate guanylate cyclase-C (GC-C) receptors in intestinal epithelium, resulting in the elevation of cGMP intracellularly and extracellularly. This receptor is the target for heat-stable enterotoxin (STa) of \textit{Escherichia coli}. Activation of GC-C results in stimulation of chloride and bicarbonate secretion through cGMP-dependent phosphorylation of CFTR, resulting in the opening of chloride channels, and it results in inhibition of Na\textsuperscript{+} absorption through blockade of an apical Na\textsuperscript{+}/H\textsuperscript{+} exchanger.\textsuperscript{151,152} The principal effector of ion transport is cGMP-dependent protein kinase type II. In addition to the secretory effects, linaclotide induces extracellular release of cGMP that inhibited visceral nociceptors.\textsuperscript{153} Linaclotide accelerates colonic transit, enhances intestinal secretion, and improves symptoms of constipation and abdominal pain in phase 2b and phase 3 trials of patients with chronic constipation and IBS-C.\textsuperscript{154-162} It is approved for the treatment of IBS-C (290 µg/d) by the FDA, the European Medicines Agency, Health Canada, COFEPRIS (Mexico), and the Swiss Agency for Therapeutic Products (Swissmedic), and for the treatment of chronic constipation (145 µg/d) by the FDA, Health Canada, and COFEPRIS (Mexico).

Plecanatide is another GC-C currently being developed for IBS-C and chronic constipation.\textsuperscript{163} In a large (n = 946)
12-week, phase 2b study, plecanatide was effective in treating the symptoms of constipation, particularly at the highest dose (3 mg once daily).164

Tenapanor is an inhibitor of sodium-hydrogen exchanger 3 that blocks absorption of Na⁺ through the sodium-hydrogen exchanger 3 transporter. In a phase 2b clinical trial in IBS-C, tenapanor, 50 mg twice daily, increased spontaneous bowel movements responder rate and was well tolerated.165

Bile Acid Modulation

Delivery of bile acids into the colon due to inadequate (less than the normal approximately 95%) ileal reabsorption results in secretory diarrhea by increasing permeability, activating adenylate cyclase, and increasing colonic motility.166 It is estimated that approximately 25% of patients diagnosed with IBS-D actually have bile acid malabsorption.167 Treatment of these patients with bile acid sequestrants may be helpful, although well-controlled studies are lacking (see in subsection Bile acid binders).

Given the pharmacologic effects of bile acids on GI function, a novel approach for treatment of chronic constipation involves selective inhibition of the ileal bile acid transporter (also called apical Na⁺-dependent bile acid transporter) with elobixibat, resulting in greater delivery of bile acids to the colon. This drug accelerated colonic transit, significantly improved stool consistency, constipation rating, ease of stool passage, and reduction of straining; and significantly increased stool frequency and improved constipation-related symptoms over 8 weeks of treatment.168,169 Long-term exposure of patients to high colonic bile acids after partial ileal bypass for hyperlipidemia is not associated with increased prevalence of colorectal cancer at 5-year or 25-year follow-up.170

Peripheral Acting μ-opioid Receptor Antagonists in Opioid-Induced Constipation

Peripheral acting μ-opioid receptor antagonists, such as N-methylaltrexone and naloxegol are designed to reverse the peripheral effects of opioids without compromising central opioid analgesia.

Although efficacy in OIC has been demonstrated,171,172 alvimopan has only been approved by the FDA for the short-term treatment of postoperative ileus because of a suspected increase of cardiovascular events in one long-term trial. Methylaltrexone is currently available in subcutaneous injection and approved for use in palliative care patients and chronic noncancer pain. An oral form of methylaltrexone also appears to be effective for OIC, but is not yet approved by regulators.

Naloxegol is an oral therapy that is approved by the FDA for treatment of OIC in adult patients with chronic noncancer pain. In 2 large phase 3 clinical trials, 25 mg once daily of naloxegol significantly improved OIC response rates compared with placebo. Naloxegol, 12.5 mg once-daily dose, also showed efficacy, though it met statistical significance in only 1 of the 2 trials.173,174 Other peripheral acting μ-opioid receptor antagonists in clinical development are naldemedine and TD-1211. These agents are summarized in Supplementary Table 5.

Other Medications in Opioid-Induced Constipation

Prucalopride,175 lubiprostone,176,177 and the experimental GC-C agonist, SP-333,178 are also potentially efficacious in treatment of OIC. Of these, only lubiprostone at a dose of 24 μg twice daily is approved by the FDA for the treatment of OIC.

Chronic Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome

In the absence of mucosal diseases, such as celiac and inflammatory bowel diseases, chronic diarrhea generally results from increased intestinal or colonic motility or secretion, increased colorectal sensitivity, or alterations of the intestinal content (bile and short-chain fatty acids or the microbiome) and barrier function.

Current Drug Treatments for Chronic Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome

μ-Opioid receptor agonists. The μ-opioid receptor agonist loperamide has limited ability to penetrate the blood—brain barrier and inhibits secretion, reduces colonic transit, and increases resting anal sphincter tone.179 In contrast to loperamide, which is available over-the-counter, diphenoxylate can cross the blood—brain barrier and, therefore, is combined with atropine to reduce abuse potential and is available only by prescription. While both μ-opioid receptor agonists reduce diarrhea, particularly acute diarrhea, neither has been subjected to high-quality clinical trials in IBS-D.180 In the case of loperamide, several small studies have shown improvement in diarrhea-related symptoms associated with IBS-D, but have not evaluated individual or global symptoms in IBS-D. Adverse effects are rare, but include bladder dysfunction, glaucoma, and tachycardia.

Bile acid binders. Bile acid binders (cholestyramine, 4 g 3 times daily, and off-label colesevelam, 625 mg, 1–3 tablets bid) are indicated for bile acid diarrhea and those with IBS-D and bile acid diarrhea.181 Cholestyramine granules are often poorly tolerated, owing to poor taste and sticking to teeth.

5-Hydroxytryptamine type 3 receptor antagonists. 5-HT₃ receptor antagonists, such as alosetron, delay orocecal and colonic transit times and reduce colonic compliance, but not sensitivity to isobaric distention.182–184 Several clinical studies confirmed the efficacy of alosetron in IBS-D.29 Alosetron was temporarily withdrawn due to suspected association with ischemic colitis185; it is now available for restricted use only in the United States. Other 5-HT₃ antagonists (such as ondansetron), approved for the treatment of chemotherapy-induced nausea and vomiting, are
often used as off-label treatment for IBS-D. Ondansetron was shown to be effective in IBS-D.\textsuperscript{186}

**Psychoactive agents.** Psychoactive agents with anticholinergic effects are commonly used off label in IBS-D. These are reviewed elsewhere (Biopsychosocial Aspects of FGIDs).

**Novel Drugs in Development or Recently Approved for Chronic Diarrhea and Diarrhea-Predomination Irritable Bowel Syndrome**

**5-Hydroxytryptamine type 3 receptor antagonists.** Ramecetron slows colonic transit and reduces pain sensation in animal models subjected to stress.\textsuperscript{187,188} Ramosetron (5 µg and 10 µg) was tested in 4 studies of approximately 1300 patients with IBS-D and was superior to placebo in global relief of symptoms, with similar efficacy in men and women. Constipation and hard stool occurred in approximately 5% of patients.\textsuperscript{189–193} Ramosetron, 5 µg once daily, is as effective as the antispasmodic, mebeverine, 135 mg 3 times daily, in male patients with IBS-D.\textsuperscript{194} To date, ramosetron has not caused ischemic colitis.

**Nonabsorbable antibiotics.** Rifaximin is a minimally absorbed antibiotic that is FDA-approved for treating traveler’s diarrhea and hepatic encephalopathy; it is also approved for IBS-D. In 2 large, phase 3 trials, rifaximin, 550 mg tid for 2 weeks, significantly improved adequate relief of IBS symptoms and abdominal bloating, as well as the FDA Responder End point for IBS-D during the 10 weeks after treatment. Patients receiving rifaximin had an approximately 10% greater likelihood of being a responder for adequate relief of IBS symptoms and bloating than patients receiving placebo.\textsuperscript{195} A meta-analysis that included 3 additional clinical trials also found improvement of global IBS symptoms and bloating, but no significant effect on bowel function.\textsuperscript{196} Retreatment with rifaximin is also efficacious.\textsuperscript{197}

**Mixed µ-opioid receptor agonist and δ-opioid receptor antagonist (eluxadoline).** The combination of mixed µ-opioid receptor agonist and δ-opioid receptor antagonist eluxadoline has been studied in phase 2 and two phase 3 clinical trials for 26 and 52 weeks in IBS-D patients.\textsuperscript{198,199} A greater percentage of patients receiving 100 mg eluxadoline met responder definitions proposed by regulatory agencies, compared with patients receiving placebo. Few cases of pancreatitis and sphincter of Oddi spasm were reported in patients at high risk (eg, history of alcohol abuse or history cholecystectomy). The drug is approved by the FDA, and risk–benefit is being carefully watched.

**Serotonin synthesis inhibition.** LX-1031 is an oral tryptophan hydroxylase (TPH) inhibitor that reduces synthesis of 5-HT peripherally,\textsuperscript{200} as it does not cross the blood–brain barrier and, thus, avoids risk of depression. In a 4-week, phase 2 trial, LX-1031 dose-dependently reduced 5-HT, and there was correlation with adequate relief and improved stool consistency with the 1000-mg dose group.\textsuperscript{201} There appears to be wide variability in effect of the drug, possibly related to TPH1 polymorphisms and the observation that 15 of 43 patients who showed a fall in urinary 5-hydroxyindoleacetic acid excretion responded better than those who did not show a fall in urine 5-hydroxyindoleacetic acid. No phase 3 trials have been reported to date.

**Tachykinin receptor antagonists.** Three distinct receptors, neurokinin-1, neurokinin-2, and neurokinin-3, mediate the biological effects of endogenous tachykinins, substance P, and neurokinin A and B in the gastrointestinal tract. Through their locations on intrinsic nerves, extrinsic nerves, inflammatory cells, and smooth muscle, inhibition of tachykinin receptors has the potential to inhibit motility, sensitivity, secretion, and inflammation in the gastrointestinal tract.\textsuperscript{202,203} Tachykinin 1 receptor antagonists also have antiemetic properties.\textsuperscript{204}

An NK₂ receptor antagonist, ibodutant (1, 3, and 10 mg, once daily), was compared with placebo for 8 weeks in 559 patients with IBS-D. There was significant effect of the 1 mg/d dose in females in a prespecified analysis.\textsuperscript{205} Ibodutant is currently being evaluated in phase 3 studies in female patients with IBS-D.

**Muscarnic type 3 receptor antagonists.** There are beneficial pharmacodynamic effects of this class of medications that can relieve chronic diarrhea: darifenacin retarded human small bowel and colonic transit, otilonium reduced rectal sensation, and hyoscine (nonselective) reduced enterocyte secretion.\textsuperscript{206–208} Clinical trials show greatest effect of otilonium on abdominal sensation rather than bowel dysfunction in IBS.\textsuperscript{208,209} A cross-over design trial showed similar efficacy of solifenacin and ramosetron.\textsuperscript{210}

**Carbon adsorbent: AST-120.** AST-120 consists of porous, spherical carbon particles that adsorb substances in the lumen that can cause secretion (eg, bacterial toxins and bile acid products).\textsuperscript{211} In a phase 2, 8-week treatment trial, AST-120 transiently reduced pain and bloating in 115 patients with IBS-D or IBS-alternating, however, stool consistency was not significantly improved.\textsuperscript{212}

**Mast cell stabilizers.** The rationale for this class of medications is supported by mast cell activation and hyperplasia in the jejunal mucosal biopsies in IBS-D patients.\textsuperscript{213}

Disodium cromoglycate reduced release of tryptase from jejunal biopsies, reduced expression of toll-like receptor 2 and 4, and improved bowel function in IBS-D.\textsuperscript{214,215} In an earlier study of 66 IBS-D patients with food intolerance assessed by skin prick test, disodium cromoglycate, 250 mg 4 times daily, plus exclusion diet, was associated with prolonged symptomatic benefit compared with exclusion diet alone.\textsuperscript{216}

Ketotifen, a mast cell stabilizer with antihistamine effects, had beneficial effects on pain, bloating, flatulence, diarrhea, quality of life, sleep, and sexual functioning, but it induced sedation and drowsiness. The precise mechanism of action is unclear, because increased mast cell tryptase release from rectal biopsies was not observed in the IBS patients and histamine and tryptase release were not altered by ketotifen.\textsuperscript{217}

**Mesalamine derivatives.** Mesalamine reduced total colonic mucosal immunocytes and mast cells and mucosal release of interleukin 1β, histamine, and tryptase in IBS
patients. Clinical efficacy is unclear: 2 of 4 small clinical trials suggest it may be beneficial in IBS patients, including some benefit on bowel function. Two recent larger trials both failed to demonstrate significant efficacy in IBS-D.

**Farnesoid X receptor agonist obeticholic acid.** In an open-label trial, obeticholic acid improved stool consistency and bowel function index in patients with bile acid diarrhea.

**Glutamine.** Patients with IBS-D have increased permeability, and symptomatic IBS patients have decreased intestinal glutamine synthetase levels. In a preliminary report of a placebo-controlled trial of 10 g glutamine tid in 61 IBS-D patients with high intestinal permeability and reduced claudin-1 expression in intestinal biopsies, the glutamine arm was associated with improved abdominal pain, bloating, and diarrhea, and restored intestinal permeability.

**Visceral Sensation, Functional Abdominal Pain, and Irritable Bowel Syndrome—Related Pain**

Some medications that are discussed here because of their efficacy in the treatment of bowel dysfunction may also be independently efficacious in the relief of pain.

**Current Treatments**

**Antispasmodics.** Muscarinic receptor antagonists and smooth muscle relaxants are used in most countries for the treatment of IBS. Meta-analysis suggests they are superior to placebo in IBS-related pain, although the quality of trials has been questioned.

**Guanylate cyclase-C agonist.** Linaclotide has demonstrated improvement in abdominal pain in 2 large, phase 3 studies in IBS-C, with one trial extending treatment out to 26 weeks.

**Psychoactive agents.** Antidepressants are commonly used to treat chronic functional abdominal pain syndromes, and a Cochrane meta-analysis suggests efficacy of antidepressants in IBS. In randomized controlled trials, low-dose tricyclic antidepressants have demonstrated some improvement in global improvement in abdominal pain. However, the quality of the evidence is considered low due to the generally weak trial designs.

There is no approval of any psychoactive drug for specific IBS therapy, but some agents, such as amitriptyline, have approval in many countries for neuropathic pain therapy.

**Future Treatments for Centrally Mediated Abdominal Pain or Irritable Bowel Syndrome—Related Pain**

**Pregabalin.** The α2δ-ligand pregabalin was shown to increase distension sensory thresholds to normal levels in IBS patients with rectal hypersensitivity. Studies evaluating effects on clinical symptom end points in centrally mediated abdominal pain syndrome, formerly known in Rome III as functional abdominal pain syndrome, are awaited. Histamine1-receptor antagonists. A nonselective, histamine H1-receptor antagonist, ebastin, was tested in a 12-week, placebo-controlled trial of 55 patients and was associated with considerable relief of symptoms in 46% of the ebastin group and 12% of the placebo group. There were also lower average abdominal pain scores with ebastin.

**Other Agents for Motility and Functional Gastrointestinal Disorders**

Supplementary Table 6 and Figure 4 summarize new or promising drugs targeting motility and secretion.

**Role of Biomarkers in Individualizing Therapy in Irritable Bowel Syndrome**

The article “Design of Treatment Trials” addresses the potential of biomarkers in individualizing therapy for IBS. There have been a number of reviews discussing the potential role of biomarkers in IBS. Biomarkers are objectively measurable indicators of normal or pathologic processes or pharmacologic responses to a therapeutic intervention.

Biomarkers should meet basic requirements, such as a reasonable diagnostic performance, noninvasiveness, reproducibility, low costs, and applicability on a large scale. Biomarkers may identify pathophysiologic mechanisms that are present only in subsets of patients. Clearly, the multifactorial nature of IBS will necessitate the development of biomarkers for subgroups, just as bowel function subtype can identify only a subgroup of patients with IBS-C, IBS-D, or IBS with mixed bowel habits.

For example, the biomarker for total fecal bile acid excretion over 48 hours (low labeled homocholic acid taurocholate retention, or high fecal bile acid excretion) may allow selection of IBS-D patients to receive interventions that alter bile acid excretion, such as bile acid sequestrants. The proof of this principle is demonstrated by the recent observation in IBS-D patients with high fecal bile acid excretion that colesvelam, 1.875 g bid, improved stool consistency and increased hepatic bile acid synthesis, thereby avoiding worsening of steatorrhea. Future research may target patients with specific pathophysiologic (eg, increased expression of mast cells, high mucosal serotonin levels, high fecal proteases, alterations in the microbiome, or barrier function).

**Supplementary Material**

Note: The first 50 references associated with this article are available below in print. The remaining references accompanying this article are available online only with the electronic version of the article. Visit the online version of *Gastroenterology* at www.gastrojournal.org, and at http://dx.doi.org/10.1053/j.gastro.2016.02.029.
References


Glossary

Acetylcholinesterase: an enzyme (more precisely a hydrolase) that hydrolyzes acetylcholine.

Allodynia: a form of hypersensitivity with an abnormal pain response to an innocuous or non-noxious afferent signal.

ASBT: apical sodium dependent bile acid transporter.

Bioavailability: one of the main pharmacokinetic properties of a drug: it is the fraction of an administered dose of drug that reaches the systemic circulation, eg, after oral administration, with respect to the dose that would be available if the drug were given by the intravenous route (which implies 100% bioavailability).

Biomarker: objectively measurable indicator of normal or pathological processes, or pharmacological responses to a therapeutic intervention; it may be used for diagnostic purposes or to evaluate drug activity/efficacy.

Blood-brain barrier: a highly selective barrier that separates the circulating blood from the extracellular fluid in the central nervous system.

CYP450: cytochrome P450 enzyme system, responsible for drug metabolism.

FXR: farnesoid X receptor, also known as bile acid receptor; it is highly expressed in the liver and in the intestine.

G proteins: G proteins (guanine nucleotide-binding proteins) are a family of proteins acting as molecular switches in cells; they are involved in the transmission of signals from stimuli arising outside a cell to the inside.

hERG: human ether-a-go-go related gene, encoding a potassium channel responsible for cardiac repolarization; its blockade may cause arrhythmias.

5-HT: serotonin, or 5-hydroxytryptamine.

Hyperalgesia: increased sensitivity to pain.

Hypersensitivity: enhanced sensitivity.

Intestinal permeability: a normal function of the gut wall, which exhibits “permeability,” ie, allows nutrients to pass through the gut, while also maintaining a barrier function to keep away potentially harmful substances (such as antigens).

PAMORA: peripherally active µ-opioid receptor antagonist.

Pharmacodynamics: the branch of pharmacology studying the mechanisms of drug action and the relationship between a drug concentration and its effect.

Pharmacogenetics: the study of individual variations in DNA sequence related to drug response.

Pharmacogenomics: the study of the variability of the expression of individual genes relevant to disease susceptibility as well as drug response at cellular, tissue, individual, or population levels (a broader term when compared to pharmacogenetics).

Pharmacokinetics: the branch of pharmacology studying the fate of substances (absorption, distribution, metabolism, and elimination) administered externally to a living organism: substances may be drugs as well as toxic substances.

Polymorphism: natural variations in a gene, DNA sequence, or chromosome that have no adverse effects on the individual and occur with fairly high frequency in the general population. However, single nucleotide polymorphisms in the human genome may correlate with disease, drug response, and other phenotype.

Pharmaco-therapeutics: the practice of the use of drugs to achieve the best possible therapeutic result.

Pharmacokinetics: the branch of pharmacology studying the mechanisms of drug action and the relationship between a drug concentration and its effect.

Pharmacogenetics: the study of individual variations in DNA sequence related to drug response.

Preclinical Pharmacology, Toxicology, and Concepts in Development of Novel Therapeutic Agents

This section outlines some general pharmacodynamic, pharmacokinetic, and safety aspects that are important for the development of new drugs for FGIDs.

The Pharmacodynamic Target

Drug selectivity. Selectivity refers to the ability of a compound to interact with only one receptor subtype, leaving other receptors unaffected at concentrations achieved at clinically used doses, thereby avoiding side effects.

Considerations of drug selectivity should appraise all biological effects of a drug, not just in the digestive tract. For example, cisapride was a partial 5-HT4 receptor agonist,243 a 5-HT3 receptor antagonist (both of which convey potentially beneficial GI effects), and a fairly potent hERG (human ether-a-go-go related gene) K+ channel blocker.244

Due to the multifactorial pathophysiology of FGIDs, single receptor modulating drugs might be less efficacious than balanced modulation of multiple targets, which may provide a superior therapeutic effect and side-effect profile compared with the action of a selective ligand.245 A key challenge in the design of a ligand with multiple actions is to achieve a balanced potency and activity at each target of interest and a suitable pharmacokinetic profile. The less selective a ligand is, the harder it is to predict toxicity or its mechanistic explanation. This may jeopardize the development and regulatory approval of less-selective ligands.

Because more than one mechanism may be responsible for the same symptom in FGIDs, the selective approach to
relieving symptoms or groups of symptoms (eg, pain and constipation or diarrhea) was efficacious in approximately 60% of patients with tegaserod or alosetron or linaclotide or lubiprostone. Diversity in underlying mechanisms rather than inadequate dosing is more likely the reason for lack of efficacy in approximately 40% of patients. Hence, there is the need to consider using multiple therapies or “designed” multiple ligands to enhance the benefit/risk ratio.

**Pharmacodynamic vs Pathophysiologic Target**

Theoretically, ideal new drugs should target the entire pathophysiologic mechanism(s) contributing to the functional disorder rather than only an individual part or a specific receptor. Thus, nonselective agents designed to modulate multiple targets contributing to the whole pathophysiologic process (eg, dysmotility, sensory disorder, and inflammation) would potentially be advantageous over highly selective medications addressing a single mechanism. Should appropriate patient subgroups be recruited to test the therapeutic properties of a medication, even if this might reduce the generalizability of the trial results? At the present time, there is no drug that addresses all the mechanisms underlying patients’ symptoms. In the future, the selection of patients based on valid biomarkers (see section Pharmacogenomics in IBS) rather than symptoms would usher in an era of greater personalization of treatment based on the affected mechanism.

**Concepts for developing functional gastrointestinal disorder drugs.** There are at least 3 key aspects that deserve rethinking in FGID drug development. First, functional gut disorders have multifactorial pathophysiology, which should be addressed by designed multiple ligands. Second, by restricting the drug to the intraluminal compartment, systemic adverse effects are avoided. Peripheral restriction of the effects of the medication can be achieved by excluding penetration of the blood—brain barrier (eg, peripherally acting μ-opioid receptor antagonists or eluxadoline, a locally active μ-opioid receptor agonist and δ-opioid receptor antagonist). A third approach is to develop drugs acting exclusively in the GI tract and liver (eg, farnesoid X receptor agonists, such as obeticholic acid).

The gut microbiome is a target for therapeutic intervention, the microbiome may itself affect the actions of the drug, and drugs may alter the microbiome. Insight into the actions of lubiprostone provides an example of possible interaction with the microbiome. In an ex vivo model, lubiprostone decreased the thickness of the inner mucus layer in both proximal and distal colon and, more importantly, caused qualitative changes of stool microbiome by increasing abundance of *Lactobacillus* and *Alistipes*, which theoretically reflect a more “protective” microbiome with anti-inflammatory properties. These findings are consistent with previous in vitro and in vivo data and suggest that active mucosal hydration functions as a primitive innate epithelial defense mechanism; and that intestinal microbiome could be a potential target in IBS.

Reverse pharmacokinetics (Figure 3) and reverse pharmacodynamics are innovative ways to develop new drugs, especially those from natural sources. Classical pharmacokinetics were designed to determine the desirable pharmacokinetic features of a new chemical entity to be developed for clinical use. However, for most natural compounds already used in traditional medicine, the molecular targets are unknown and, without exact knowledge, it is difficult to optimize the pharmacokinetic profile of drug candidates and fulfill current regulatory standards. The concept of “reverse pharmacokinetics” is based on the thorough pharmacokinetic assessment of natural medicines, for which purported clinical benefits are documented by historical use, while target tissues and mechanisms remain unclear. Examples would be curcumin in inflammatory conditions or STW5 (Iberogast) in FD. Thus, the purpose of reverse pharmacokinetics is to provide clues for target identification and mechanistic understanding of agents tested.

After oral administration, the drug’s pharmacokinetics depend on intestinal and hepatic metabolism, as well as drug delivery to intestinal epithelia or specialized intestinal cells, such as M cells, goblet cells, and dendritic cells.

**Safety Aspects**

Apart from the standard safety evaluations of every new drug, 2 new concerns deserve special attention because of recent experience. Cisapride resulted in tachyarrhythmia associated with prolongation of the QT interval of the electrocardiogram due to blockade of the hERG K+ channels. Alosetron and cilansetron were associated with ischemic colitis in about 1 in 1000 patients. Although these are very rare events, even a low risk may not be acceptable from a regulatory perspective for drugs that provide relief of nonfatal diseases, such as FGIDs. The drug development process should identify such undesired effects as early as possible. Finally, the potential for drug interactions is relevant, given the polypharmacy and frequent use of psychotropic agents (which often depend on CYP2D6 metabolism).

**Pharmacogenetics in Irritable Bowel Syndrome**

In addition to understanding the pathophysiology of IBS, insight into pharmacogenetics and, specifically, the manner in which genetic abnormalities influence drug activity, binding, and metabolism has become central to proposing control mechanisms in IBS and may impact the management of individual IBS patients.

**Drug Metabolism and Pharmacogenetics**

The enzymatic metabolism of drugs involves modifications of functional groups (phase I reactions, such as oxidation, dehydrogenation, and esterification) or conjugation with endogenous substituents (phase II reactions). The most common and most relevant drug modifications in IBS result from CYP2D6 metabolism, which is an example of phase I drug metabolism. There are distinct geographic variations of the CYP genes, suggesting that population
substructure can strongly affect the variation in pharmacogenetic loci\(^\text{460}\) (Supplementary Table 7).

The number of functional alleles (≥3, 2, 1, and 0) determines whether CYP2D6 metabolism is ultrarapid, extensive, intermediate, or poor. About 1% of Asians and 5%–10% of Caucasians (Figure 2) are poor metabolizers.\(^\text{258}\) Gene multiplication may result in 3 or more functional alleles, and ethnic groups with ≥10 functional alleles\(^\text{64}\) are infrequent among northern Europeans, rarer in Chinese,\(^\text{259}\) but frequent (as high as 29%) in East African populations.\(^\text{260}\) The most common nonfunctionalalleles are CYP2D6*3, CYP2D6*4, CYP2D6*5, and CYP2D6*6, which constitute approximately 98% of nonfunctional alleles in Caucasians.\(^\text{261}\)

CYP2D6 metabolism impacts the extensively used tricyclic antidepressants and selective serotonin reuptake inhibitors in FGIDs and visceral hypersensitivity.\(^\text{262}\) Although not yet fully appreciated in IBS practice, a multitude of drugs are metabolized by CYP2D6, and there are many drugs that inhibit or activate CYP2D6, thus creating the possibility of significant drug interactions. In some ethnic groups, CYP2D6 testing may be warranted if antidepressants will be prescribed.\(^\text{263}\)

The second category of pharmacogenetic modulation of drug effects in IBS reflects variations in receptors, transporters, or function of rate-limiting enzymes.

Serotonergic Pharmacogenetics

The most informative studies of pharmacogenetics in IBS revolve around 5-HTTLPR genetics and the efficacy of alosetron in normalizing colonic transit in IBS-D\(^\text{242}\) and the efficacy of tegaserod in the treatment of bowel dysfunction in IBS-C.\(^\text{66}\) Thus, the 5-HT\(_3\) antagonist aloestron is more effective when the 5-HTTLPR LL genotype results in increased SERT expression and greater 5-HTT clearance. Alosetron competes more effectively for the 5-HT\(_3\) receptor when extracellular 5-HT is lower. There is also evidence, from a study of the 5-HT\(_3\) receptor antagonist ondansetron, that the SL genotype is associated with a trend (\(P = .07\)) to effects on change in stool consistency and on the increase in whole-gut transit time in an analysis of 67 patients in a randomized, double-blind, placebo-controlled, crossover study of 5 weeks of ondansetron, 4 mg, vs placebo with dose titration allowed.\(^\text{264}\) Differences in the latter study with the results reported with alosetron may reflect the different medications, the dose titration of ondansetron, and the greater sensitivity of scintigraphy to measure colonic transit compared with radiopaque marker whole-gut transit time. Conversely, the 5-HT\(_4\) receptor agonist tegaserod results in lower efficacy in carriers of the SS genotype,\(^\text{186}\) because there is more endogenous 5-HT to complement the effects of the exogenous tegaserod in activating the 5-HT\(_4\) receptor.

Bile Acids and Pharmacogenetics in Constipation-Predominant and Diarrhea-Predominant Irritable Bowel Syndrome

In addition to the observations that genetic variations in Klotho-\(\beta\) (KLB) and, possibly, fibroblast growth factor receptor 4 (FGFR4) are associated with accelerated colonic transit in patients with IBS-D,\(^\text{265}\) variations in the same genes influence the colonic transit response to chenodeoxycholic acid in IBS-C\(^\text{266}\) and to coleselam in IBS-D patients.\(^\text{267}\)

References (Online Only)


Supplementary Figure 1. Drug discovery from natural medicines. In contrast to the traditional or classical approach, where new chemical entities are identified by screening a compound library for target-based activity followed by validation and drug development, an alternative approach is to build on the clinical evidence that a medicine derived from natural materials is efficacious and safe, and to identify the active compound, its mechanism of action and pharmacokinetics to optimize the efficacy of the natural remedy. ADME, absorption, distribution, metabolism, and excretion; PK, pharmacokinetics. This concept and figure are adapted from Hao et al.,251 with permission.
### Supplementary Table 1. Agents Directed to Amines/Receptors and Peptides to Affect Functions of the Upper and Lower Gastrointestinal Tract

<table>
<thead>
<tr>
<th>Target system/receptor</th>
<th>Type of ligand</th>
<th>Distribution of receptors</th>
<th>Pharmacologic action in animals</th>
<th>Pharmacologic action in humans</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>5-HT</strong></td>
<td>5-HT&lt;sub&gt;3&lt;/sub&gt;-receptor antagonists (eg, alosetron, ondansetron, ramosetron)</td>
<td>Intrinsic and extrinsic neurons</td>
<td>Inhibits visceral sensitivity, absorption/motility</td>
<td>Slows transit, increases colonic compliance</td>
</tr>
<tr>
<td></td>
<td>5-HT&lt;sub&gt;4&lt;/sub&gt; receptor agonists (eg, prucalopride, velusetrag, mosapride, naronapride, YKP10811)</td>
<td>Enteric neurons, smooth muscle cells</td>
<td>Enhances secretion and motility, reduces visceral sensitivity</td>
<td>Accelerates transit, increases colonic HAPC and gastric accommodation, reduces inhibition of RIII reflex during rectal distension</td>
</tr>
<tr>
<td></td>
<td>5-HT&lt;sub&gt;1A&lt;/sub&gt; receptor agonists (eg, buspirone)</td>
<td>Enteric neurons, extrinsic afferent neurons</td>
<td>Inhibits motility and enhances compliance</td>
<td>Increases accommodation; central actions anxiolytic agent and tranquilizer</td>
</tr>
<tr>
<td><strong>ACh (Muscarinic)</strong></td>
<td>M&lt;sub&gt;3&lt;/sub&gt; receptor antagonists</td>
<td>Smooth muscle</td>
<td>Increases smooth muscle relaxation, compliance</td>
<td>No published data</td>
</tr>
<tr>
<td></td>
<td>M&lt;sub&gt;1&lt;/sub&gt; and M&lt;sub&gt;2&lt;/sub&gt; receptor antagonists</td>
<td>Enteric neurons and smooth muscle</td>
<td>Increases gastric emptying</td>
<td>May enhance accommodation</td>
</tr>
<tr>
<td></td>
<td>Acetylcholinesterase inhibitors (eg, acotiamide, itopride)</td>
<td>Enteric neurons and smooth muscle</td>
<td>Increases gastric emptying</td>
<td>Increases gastric emptying and accommodation</td>
</tr>
<tr>
<td><strong>Adrenoceptors</strong></td>
<td>β&lt;sub&gt;2&lt;/sub&gt;-Adrenoceptor agonists</td>
<td>Smooth muscle</td>
<td>Inhibits motility</td>
<td>No published data</td>
</tr>
<tr>
<td></td>
<td>α&lt;sub&gt;2&lt;/sub&gt;-Adrenoceptor agonists</td>
<td>Enteric neurons and enterocytes</td>
<td>Reduces secretion, enhances compliance, and reduces motility and tone</td>
<td>Reduces secretion, enhances compliance, and reduces motility, tone, and sensation</td>
</tr>
<tr>
<td><strong>Dopamine</strong></td>
<td>D&lt;sub&gt;2&lt;/sub&gt;-receptor antagonists (eg, domperidone, levosulpiride, metoclopramide, itopride)</td>
<td>Area postrema, smooth muscle, enteric neurons</td>
<td>Contracts muscle</td>
<td>Antiemetic, prokinetic, reduces sensation?</td>
</tr>
<tr>
<td><strong>Motilin</strong></td>
<td>Motilides</td>
<td>Smooth muscle, enteric neurons</td>
<td>Stimulates motility</td>
<td>Stimulates motility and transit</td>
</tr>
<tr>
<td><strong>Ghrelin</strong></td>
<td>Ghrelin agonists</td>
<td>Hypothalamus, ?, ?&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Stimulates appetite</td>
<td>Accelerates gastric emptying, reduces gastric accommodation</td>
</tr>
<tr>
<td><strong>Cannabinoid</strong></td>
<td>δ-9-Tetrahydrocannabinol</td>
<td>Enteric neurons</td>
<td>Slows gastrointestinal transit</td>
<td>Delays gastric emptying; antiemetic properties</td>
</tr>
<tr>
<td><strong>Opioid</strong></td>
<td>μ-Receptor agonists (eg, loperamide)</td>
<td>Nucleus tractus solitarius neurons</td>
<td>Reduces intestinal secretion and transit</td>
<td>Slows colonic transit, antidiarrheal, increases resting anal tone</td>
</tr>
<tr>
<td></td>
<td>μ-Receptor antagonists (eg, naloxone, methylprednisolone, alvimopan, naxolegol)</td>
<td>Enteric neurons, afferent neurons, and inflammation</td>
<td>Reverses opioid effects on motility</td>
<td>Accelerates colonic transit, reverses OIC, reduces duration of PO ileus</td>
</tr>
<tr>
<td></td>
<td>k-Receptor agonists (eg, fedotozine, asimadoline)</td>
<td>Enteric neurons and afferent neurons</td>
<td>Reduces sensation, variable effect on motility</td>
<td>Reduces sensation</td>
</tr>
<tr>
<td><strong>Somatostatin</strong></td>
<td>SSR-2 receptor agonists (eg, octreotide, lanreotide)</td>
<td>Enteroendocrine cells, submucosal neurons, myenteric neurons</td>
<td>Retards transit, reduces affereing firing and sensation</td>
<td>Slows transit, reduces sensitivity, enhances absorption</td>
</tr>
<tr>
<td><strong>Tachykinin</strong></td>
<td>NK&lt;sub&gt;1&lt;/sub&gt;-receptor antagonists (eg, aprepitant)</td>
<td>Enteroendocrine cells, interstitial cells of Cajal, smooth muscle, immune cells</td>
<td>Inhibits motility, fluid secretion, vagal afferent sensation, and inflammation</td>
<td>Antiemetic</td>
</tr>
<tr>
<td></td>
<td>NK&lt;sub&gt;2&lt;/sub&gt;-receptor antagonists (eg, ibudutant)</td>
<td>Enteroendocrine cells, smooth muscle, extrinsic afferent</td>
<td>Inhibits motility</td>
<td>Inhibits NK&lt;sub&gt;1&lt;/sub&gt;-induced motility</td>
</tr>
<tr>
<td></td>
<td>NK&lt;sub&gt;3&lt;/sub&gt;-receptor antagonists (eg, talnetant)</td>
<td>Enteroendocrine cells, extrinsic afferent</td>
<td>Inhibits motility and sensation</td>
<td>No published data</td>
</tr>
<tr>
<td>Target system/receptor</td>
<td>Type of ligand</td>
<td>Distribution of receptors</td>
<td>Pharmacologic action in animals</td>
<td>Pharmacologic action in humans</td>
</tr>
<tr>
<td>---------------------------</td>
<td>--------------------------------</td>
<td>---------------------------</td>
<td>-----------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------</td>
</tr>
<tr>
<td>Guanylate cyclase-C</td>
<td>GC-C agonists (eg, linaclotide, plecanatide)</td>
<td>Luminal side of the enteric mucosa</td>
<td>Induces secretion of $\text{HCO}_3^-$, $\text{Cl}^-$, $\text{H}_2\text{O}$ and inhibits visceral nociceptors via cGMP</td>
<td>Looser stool consistency, accelerates colonic transit, decreases visceral pain</td>
</tr>
<tr>
<td>Chloride channels</td>
<td>ClC$_2$ activators (eg, lubiprostone)</td>
<td>Enteric mucosa</td>
<td>Induces secretion of bicarbonate, chloride, $\text{H}_2\text{O}$</td>
<td>Looser stool consistency, accelerates colonic transit</td>
</tr>
<tr>
<td>NHE$_3$ transporter</td>
<td>NHE$_3$ inhibitor (eg, tenapanor)</td>
<td>Enteric mucosa</td>
<td>Inhibits absorption of $\text{Na}^+$</td>
<td>Improves stool consistency</td>
</tr>
</tbody>
</table>

ACh, acetylcholine; ClC, chloride channel; HAPC, high-amplitude propagated contraction; NHE, sodium-hydrogen exchange; NK, tachykinin; OBD, opioid bowel dysfunction; PO, postoperative; SSR, somatostatin receptor.

*a*The question mark (?) refers to a hypothetical action or site of action that is not proven.
### Supplementary Table 2. Pharmacologic Actions of Psychotropic Drugs on Monoamine Reuptake and Receptors

<table>
<thead>
<tr>
<th>Drug</th>
<th>Neurotransmitter reuptake blockade</th>
<th>Receptor blockade</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>5-HT</td>
<td>Norepinephrine</td>
</tr>
<tr>
<td>Tricyclic agents</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amitriptyline</td>
<td>++</td>
<td>+</td>
</tr>
<tr>
<td>Imipramine</td>
<td>++</td>
<td>+++</td>
</tr>
<tr>
<td>Desipramine</td>
<td>+++</td>
<td>+++</td>
</tr>
<tr>
<td>Clomipramine</td>
<td>+++</td>
<td>+++</td>
</tr>
<tr>
<td>SSRIs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluoxetine</td>
<td>+++</td>
<td>+</td>
</tr>
<tr>
<td>Paroxetine</td>
<td>+++</td>
<td>+++</td>
</tr>
<tr>
<td>Sertraline</td>
<td>+++</td>
<td>+</td>
</tr>
<tr>
<td>Citalopram</td>
<td>+++</td>
<td>-</td>
</tr>
<tr>
<td>SNRIs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Venlafaxine</td>
<td>+++</td>
<td>+</td>
</tr>
<tr>
<td>Duloxetine</td>
<td>+++</td>
<td>+++</td>
</tr>
<tr>
<td>Atypical agents</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bupropion</td>
<td>0</td>
<td>+</td>
</tr>
<tr>
<td>Nefazodone</td>
<td>++</td>
<td>++</td>
</tr>
<tr>
<td>Mirtazapine</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Quetiapine</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Azapirones</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Buspirone</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

\(\alpha\), \(\alpha\)-adrenoceptor; ACh, muscarinic acetylcholine receptor; D, dopamine; H, histamine; SNRIs, serotonin-norepinephrine reuptake inhibitors; SSRIs, selective serotonin reuptake inhibitors.

\(^a\)Symbols + to ++ + + + indicate increasing levels of potency.

\(^b\)\(-\) indicated weak.

\(^c\)0 indicates no effect.

\(^d\)Mirtazapine also blocks 5-HT\(_3\) receptors (++++), which reduces nausea, and it has acute anxiolytic effects in humans.
<table>
<thead>
<tr>
<th></th>
<th>Prucalopride</th>
<th>Mosapride</th>
<th>Velusetrag</th>
<th>Naronapride</th>
<th>YKP10811</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Chemistry</strong></td>
<td>Benzofuran-carboxamide</td>
<td>Benzamide</td>
<td>Quinolinone-carboxamide</td>
<td>Benzamide</td>
<td>Benzamide</td>
</tr>
<tr>
<td><strong>Selectivity and affinity for 5-HT4 receptor</strong></td>
<td>Highly selective, high affinity; weak affinity for human D2a and σ1, and mouse 5-HT3 receptors at concentrations exceeding the Ki for 5-HT4 receptors by 290-fold</td>
<td>High selectivity and affinity for 5-HT4. But major metabolite (M1) with 5-HT3-antagonistic activity</td>
<td>High affinity and selectivity for h5-HT4, over other biogenic amine receptors; &gt;500-fold selectivity over other 5-HT receptors (including h5-HT2B, h5-HT3a)</td>
<td>Specific 5-HT4 full agonist activity in the GI tract, but a partial agonist activity in the heart</td>
<td>High binding affinity to the 5-HT4 receptor; 120-fold and 6-fold lower affinity, respectively, for 5-HT2A and 5-HT2B receptors than for 5-HT4; antagonist activity at 5-HT2B receptor</td>
</tr>
<tr>
<td><strong>Hepatic metabolism</strong></td>
<td>Limited, not CYP 3A4</td>
<td>CYP 3A4</td>
<td>CYP 3A4</td>
<td>Hydrolytic esterase, not CYP 3A4</td>
<td>Oxidation of aromatic rings and N-dealkylation may involve CYP 3A4</td>
</tr>
<tr>
<td><strong>Pharmacodynamic efficacy in humans</strong></td>
<td>Accelerated colonic transit in health and in chronic constipation</td>
<td>Accelerated esophageal motility, gastric emptying and small bowel transit in health</td>
<td>Accelerated colonic transit in health in dose-related fashion</td>
<td>Accelerated colonic transit in health</td>
<td>Accelerated colon filling at 6 hours, 11/2 of ascending colon emptying, and colonic transit in functional constipation</td>
</tr>
<tr>
<td><strong>Clinical trial efficacy</strong></td>
<td>Phase 2 and 3 portfolio in chronic constipation</td>
<td>Clinical trials in dyspepsia, GERD, IBS-C, capsule endoscopy</td>
<td>Phase 2b</td>
<td>Phase 1b</td>
<td>Phase 2a study: increased stool consistency over 8 days (ITT analysis) in functional constipation</td>
</tr>
<tr>
<td><strong>Open label effectiveness</strong></td>
<td>Open label experience of ~1000 cumulative patient-years</td>
<td>Several years of market experience in Asian and South American countries</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td><strong>Arrhythmogenicity</strong></td>
<td>No arrhythmic activity in human atrial cells; inhibited hERG channel only at μM concentration (IC50 ~ 4.9×10^-6 M); no clinically relevant cardiac AEs in clinical trials of &gt;4000 humans</td>
<td>Low potency to inhibit hERG activity in clinical trials, no clinically relevant effects on QT-intervals</td>
<td>At 3 μM, no effect on hERG channel current; safety ratio vs cisapride &gt;1000-fold; no effect on QT in health or in 400 patients with constipation</td>
<td>At 100 μM, no effect on hERG channel; affinity ratio between Ikr and 5-HT4 receptors of &gt;1000-fold</td>
<td>Inhibited hERG channel only at μM concentration</td>
</tr>
<tr>
<td><strong>Cardiovascular safety including elderly</strong></td>
<td>Healthy subjects “thorough” QTc study; safety in elderly cohort 80% on CV drugs</td>
<td>Healthy subjects, no effects of mosapride on heart rate, blood pressure variabilities, autonomic nervous activity parameters, QT intervals, or QT dispersions</td>
<td>Healthy subjects “thorough” QTc study; transient increase in heart rate not different from placebo</td>
<td>Healthy subjects “thorough” QTc study</td>
<td>QTc prolonged at doses of 100 to 600 mg (target dose likely 10–20 mg)</td>
</tr>
</tbody>
</table>
**Supplementary Table 3. Continued**

<table>
<thead>
<tr>
<th>Most common adverse events</th>
<th>Prucalopride</th>
<th>Mosapride</th>
<th>Velusetrag</th>
<th>Naronapride</th>
<th>YKP10811</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diarrhea, headache</td>
<td>Diarrhea, abdominal pain, headache</td>
<td>Diarrhea, nausea, headache</td>
<td>Diarrhea, headache</td>
<td>Diarrhea, headache, borborygmi</td>
<td></td>
</tr>
<tr>
<td>Approval status</td>
<td>EMA, Canada, Mexico</td>
<td>A variety of Asian and South American countries</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Approved dose</td>
<td>2 mg/d in adults; 1 mg/d in &gt;65 years</td>
<td>5 mg tid in adults</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
</tbody>
</table>

NOTE. Adapted from Camilleri, with permission. AE, adverse event; CV, cardiovascular; EMA, European Agency for Evaluation of Medicinal Products; GERD, gastroesophageal reflux disease; hERG, human ether-á-go-go–related gene; IC₅₀, half maximal inhibitory concentration; ITT, intention to treat; Ki, dissociation constant; NA, not available (drug not approved).
**Supplementary Table 4. Comparison of Secretagogues**

<table>
<thead>
<tr>
<th></th>
<th>Lubiprostone</th>
<th>Linaclotide</th>
<th>Plecanatide</th>
<th>Tenapanor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemistry</td>
<td>Bicyclic fatty acid called a prostone</td>
<td>14 amino acid peptide, analog of guanylin and uroguanylin</td>
<td>16 amino acid peptide, analog of uroguanylin</td>
<td>Tetrahydroisoquinoline dimer</td>
</tr>
<tr>
<td>Target receptor</td>
<td>Chloride channel (ClC2); CFTR involved</td>
<td>Guanylate cyclase-C activation with CFTR-mediated secretion</td>
<td>Guanylate cyclase-C activation with CFTR-mediated secretion</td>
<td>Inhibitor of the intestinal sodium transporter NHE3</td>
</tr>
<tr>
<td>Pharmacodynamics in humans</td>
<td>Accelerated small bowel and colonic transit in health</td>
<td>Accelerated colonic transit in IBS-C in dose-related fashion</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Pharmacodynamics in humans</td>
<td>Phase II and III portfolio in chronic constipation and IBS-C</td>
<td>Phase 2b and 3 in chronic constipation and IBS-C</td>
<td>Phase 2a in chronic constipation and 2b study in IBS-C</td>
<td>Phase 2b in IBS-C</td>
</tr>
<tr>
<td>Clinical trial efficacy</td>
<td>Clinical practice experience</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Open label effectiveness</td>
<td>No arrhythmic activity</td>
<td>Low bioavailability</td>
<td>Low bioavailability</td>
<td>Low bioavailability</td>
</tr>
<tr>
<td>Cardiovascular safety</td>
<td>Healthy subjects “thorough” QTc study</td>
<td>Healthy subjects “thorough” QTc study</td>
<td>Phase I safety</td>
<td>Safe on ECG studies</td>
</tr>
<tr>
<td>Most common adverse events</td>
<td>Nausea, diarrhea</td>
<td>Diarrhea</td>
<td>Diarrhea</td>
<td>Diarrhea</td>
</tr>
<tr>
<td>Potential other actions</td>
<td>Mucosal protection</td>
<td>Anti-nociceptive effects on afferent nerves</td>
<td>Anti-inflammatory, anti-apoptotic</td>
<td>—</td>
</tr>
<tr>
<td>Approval status</td>
<td>24 µg bid for constipation</td>
<td>FDA, EMA, Canada, Mexico</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Approved doses</td>
<td>8 µg bid for constipation</td>
<td>145 µg qd for constipation</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td></td>
<td>290 µg qd for IBS-C</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**NOTE.** Adapted from Camilleri, with permission.
ECG, electrocardiogram; ND, not done; NHE3, sodium-hydrogen exchanger 3.
### Supplementary Table 5. Opioid Antagonists Used to Treat Opioid-Induced Constipation

<table>
<thead>
<tr>
<th>Drug name</th>
<th>Drug class</th>
<th>Pharmacodynamic efficacy in humans</th>
<th>Clinical trial optimal efficacy and safety</th>
<th>Approval specific to OIC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral naloxone</td>
<td>Nonselective opioid receptor antagonist</td>
<td>Reverses opioid-induced delay in orocecal and colonic transit</td>
<td>Naloxone PR formulation prevents OIC in patients receiving PR oxycodone</td>
<td>—</td>
</tr>
<tr>
<td>Methyl-naltrexone</td>
<td>PAMORA</td>
<td>Reverses effects of opioid in health and of chronic methadone treatment on orocecal transit; no effect on small intestinal or colonic transit delayed by codeine 30 mg qid in opioid-naive healthy subjects</td>
<td>Subcutaneous MNTX 0.15 mg/kg on alternate days effective in inducing laxation in patients with advanced illness and chronic noncancer pain (12 mg daily or alternate days); side effect: diarrhea</td>
<td>FDA, Canada, and EMA (for OIC in palliative care)</td>
</tr>
<tr>
<td>Naltrexone ER</td>
<td>μ-opioid antagonist as sequestered core; ratio naltrexone to morphine 4%</td>
<td>ND</td>
<td>Open-label 12-month safety of combination ER pellets of morphine (median 59 mg/d) with a sequestered naltrexone core (qd or bid); OIC 31.8%, nausea 25.2%; opioid withdrawal &lt;5%</td>
<td>—</td>
</tr>
<tr>
<td>Alvimopan</td>
<td>PAMORA</td>
<td>8-mg oral dose accelerates colonic transit and reverses effects of codeine in opioid-naive healthy volunteers receiving codeine 30 mg qid</td>
<td>0.5 mg bid dose efficacious in treating OIC; rare instances of ischemic heart disease</td>
<td>Approved for postoperative ileus</td>
</tr>
<tr>
<td>Naloxegol</td>
<td>PAMORA; PEGylated naloxone conjugate</td>
<td>Normalized morphine-induced delay in orocecal transit</td>
<td>In two phase 3, twelve-week trials in adult patients with OIC and chronic noncancer pain, naloxegol 25 mg showed significant improvement in response rate vs placebo; adverse events in &gt;9% abdominal pain and diarrhea</td>
<td>FDA, EMA</td>
</tr>
<tr>
<td>TD-1211</td>
<td>PAMORA</td>
<td>ND</td>
<td>5 mg and 10 mg/d TD-1211 increased average SBM/wk over 2 wk in OIC patients</td>
<td>—</td>
</tr>
</tbody>
</table>

**NOTE.** Adapted from Camilleri, with permission. ER, extended release; ND, not done; PAMORA, peripherally acting μ-opioid receptor antagonist; PR, prolonged release; SBM, spontaneous bowel movement.
### Supplementary Table 6. Examples of Potential Medications Targeting Motility and Secretion in Other Treatment Classes

<table>
<thead>
<tr>
<th>Drug class</th>
<th>Examples</th>
<th>Rationale and putative action</th>
<th>Pharmacodynamic (intestinal or colon)</th>
<th>Clinical efficacy: phase 2b or 3 primary endpoints</th>
<th>Safety issues/comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>TPH₁ blocker</td>
<td>LX-1031</td>
<td>Inhibits synthesis of 5-HT by blocking TPH₁ in enterochromaffin cells</td>
<td>Inhibits urinary 5-HIAA excretion; no studies of PD efficacy</td>
<td>Phase 2b trial in 155 non-IBS-C patients; 1000-mg dose improved global assessment of adequate relief and stool consistency</td>
<td></td>
</tr>
<tr>
<td>Oral carbon adsorbent</td>
<td>AST-120</td>
<td>Adsorbs luminal factors that may be causing colonic dysfunction</td>
<td>No data</td>
<td>Phase 2b study in nonconstipated IBS; reduced pain and bloating, improved stool consistency</td>
<td></td>
</tr>
<tr>
<td>a2δ ligand</td>
<td>Pregabalin</td>
<td>Reduced visceral afferent firing by blocking Ca²⁺ channels</td>
<td>Increases rectal sensation thresholds in IBS; reduces colonic sensation ratings in healthy subjects</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>NK2 receptor</td>
<td>Ibodutant</td>
<td>Inhibits visceral hypersensitivity</td>
<td></td>
<td>Phase 2b study: significant effect of the 10 mg/dose in females in a prespecified analysis</td>
<td>Nausea, vomiting</td>
</tr>
<tr>
<td>GLP-1 analog</td>
<td>Rose-010</td>
<td>Inhibits intestinal contractility</td>
<td>Reduces intestinal contractility and MMCs</td>
<td>Phase 2b study: reduced abdominal pain severity and increased number of responders in IBS</td>
<td></td>
</tr>
<tr>
<td>ASBT (IBAT) inhibitor</td>
<td>Elobixibat</td>
<td>Inhibits transport of bile acids</td>
<td>Accelerates colonic transit</td>
<td>Phase 2b study: increased SBMs and CSBMs in CIC</td>
<td></td>
</tr>
<tr>
<td>FXR agonist</td>
<td>Obeticholic acid</td>
<td>Inhibits hepatic BA synthesis</td>
<td>Increases FGF-19 production in ileum</td>
<td>Improved stool frequency and form in open-label study in BA diarrhea</td>
<td></td>
</tr>
<tr>
<td>Mast cell stabilizers</td>
<td>Disodium cromoglycate</td>
<td>Reduces tryptase and mediators that mediate immune activation, visceral hypersensitivity</td>
<td></td>
<td>Enhanced benefit from food restriction diet in IBS-D patients with food “allergies”</td>
<td></td>
</tr>
<tr>
<td>Ketotifen</td>
<td></td>
<td></td>
<td></td>
<td>Phase 2a study suggested benefit in relief of symptoms and pain in subset with baseline visceral hypersensitivity</td>
<td>Somnolence</td>
</tr>
<tr>
<td>Mesalamine</td>
<td>Mesalamine or mesalazine</td>
<td>Reduces mucosal inflammation</td>
<td>Reduces cytokines in rectal mucosal biopsies in IBS; effects on proteases of mesalamine compounds not consistently shown (positive results in n = 10 study not confirmed in n = 44 study)</td>
<td>Phase 2a small study with PD measurements showed improved overall well-being, but no significant effect on specific IBS symptoms; ineffective in 2 phase 2b larger trials</td>
<td></td>
</tr>
</tbody>
</table>

**NOTE.** Adapted from Camilleri,¹⁴⁰ with permission.

ASBT, apical sodium dependent bile acid transporter; BA, bile acid; CIC, chronic idiopathic constipation; CSBM, complete spontaneous bowel movement; FGF-19, fibroblast growth factor 19; FXR, farnesoid X receptor; GLP, glucagon-like peptide; 5-HIAA, 5-hydroxyindoleacetic acid; IBAT, ileal bile acid transporter; MMC, migrating motor complex; NK, neurokinin; PD, pharmacodynamic; SBM, spontaneous bowel movement; TPH, tryptophan hydroxylase.
<table>
<thead>
<tr>
<th>Condition</th>
<th>Drug</th>
<th>Protein (gene)</th>
<th>Alleles or polymorphisms</th>
<th>Clinical effects</th>
</tr>
</thead>
</table>
| GERD                          | PPIs                | Cytochrome P450| CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*5                                                | Wild-type predicts slower healing of esophagitis and lower cure rates of *H pylori* infection.  
|                               |                     | 2C19 (CYP2C19) |                                                                                           | CYP2C19*5 results in decreased metabolism of drug.                                |
|                               |                     |                |                                                                                           | The extensively used TCAs and SSRIs are metabolized by CYP2D6; it causes drug interaction.  
| FD, IBS                       | Tricyclic antidepressants, SSRIs | CYP2D6        | CYP2D6*3                                                                                  | In Caucasians, 5-HTTLPR may be a predictor of antidepressant response and remission, while in Asians it does not appear to play a major role.  
|                               | Tricyclic antidepressants, SSRIs | Serotonin transporter | CYP2D6*4                                                                                  |                                                                                |
|                               | Clonidine           | α2-adrenoceptor| CYP2D6*5                                                                                  | Post-clonidine responses were associated with α2A (C-1291G) SNPs for gastric accommodation and rectal sensations of gas and urgency.  
| IBS-D                         | Alosetron Colesevelam | Serotonin transporter (SLC6A4) | 5HTT-LPR rs351855 rs497501 FGFR4 KLβ | Patients with diarrhea and 5-HTTLPR *LL homozygotes may predict better response and slowing of colonic transit. Differential colesevelam effects on ascending colon half-emptying time and on overall colonic transit at 24 hours.  
| IBS-C                         | Tegaserod CDC       | Serotonin transporter (SLC6A4) | 5HTT-LPR rs376618 KLB Arg728 or rs17618244 (G allele) FGFR4 KLB                          | Patients with constipation and 5-HTTLPR *LL homozygotes may predict worse clinical response. Genetic variation in negative feedback inhibition of bile acid synthesis may affect CDC-mediated acceleration of colonic transit; rs376618 in FGFR4 was associated with differences in the effects of CDC on colonic transit; effect of rs17618244 genotype on dose response in patients with IBS-C.  

CDC, chenodeoxycholic acid; FGFR4, fibroblast growth factor receptor 4; GERD, gastroesophageal reflux disease; 5-HTTLPR, serotonin transporter linked polymorphic region.
PPI, proton pump inhibitors; SLC, solute carrier; SNP, single nucleotide polymorphisms.